Results of treatment of focal dystonia in adults with the use of botulinum toxin A3

Authors

  • Bárbaro José Martínez Brito Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara
  • Mayelín Quintero Pérez Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara
  • Mabel Reyes Rosa Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara

Keywords:

botulinum toxins, dystonic disorders, treatment outcome

Abstract

Botulinum toxin is a local drug use which worldwide has proven its effective in the treatment of focal dystonia in adults over oral medications and even surgery, provoking the opening of an outpatient clinic to treat patients without income at "Arnaldo Milian Castro" University Provincial Hospital in 2003. A descriptive, cross-sectional study was performed in patients with focal dystonia in the period of January 2004 to December 2013. Study population consisted of patients with focal dystonia attended in the botulinum toxin clinical office (171) and agreed with the sample. The most frequent age of presentation of focal dystonia was 40-60 years, females and white skin color predominated and dystonia more often treated was the blepharospasm. A month of having applied the treatment with botulinum toxin, satisfactory response predominated in the majority of dystonias, except in laryngeal dystonia by abduction. 86.5% of patients, after applying medication, they incorporated to the social and labor life.

Downloads

Download data is not yet available.

Author Biographies

Bárbaro José Martínez Brito, Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara

Especialista de I Grado en Neurología.
Profesor Instructor de la Universidad de Ciencias Médicas “Dr. Serafín Ruiz de Zárate Ruiz” de Villa Clara.

Mayelín Quintero Pérez, Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara

Licenciada en Enfermería. Profesora Instructora de la Universidad de Ciencias Médicas “Dr. Serafín Ruiz de Zárate Ruiz” de Villa Clara.

Mabel Reyes Rosa, Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara

Residente de Neurología.

References

1. Truong D, Dressler D, Hallett M, editors. Manual of Botulinum Toxin Therapy. 1 ed. [Internet]. England: Cambridge University Press; 2009 [citado 5 May 2014]. Disponible en: http://www.cambridge.org/us/academic/subjects/medicine/neurology-and-clinical-neuroscience/manual-botulinum-toxin-therapy

2. Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, et al. Evidence- based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon [Internet]. 2013 [citado 20 Abr 2014];67:94-114. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23380701

3. Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord [Internet]. 2011 [citado 20 Abr 2014];17 Suppl 1:S28-33. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21999893

4. Highlights of prescribing information [Internet]. Los Angeles: Allergan Pharmaceuticals; © Allergan 2015 [actualizado 15 Abr 2015; citado 18 May 2015]. [aprox. 37 p.]. Disponible en: http://www.allergan.com/assets/pdf/botox_pi.pdf

5. Koussoulakos S. Botulinum neurotoxin: the ugly duckling. Eur Neurol [Internet]. 2009 [citado 25 May 2014];61(6):331-42. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19365125

6. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinum toxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord [Internet]. 2011 [citado 25 May 2014];26(8):1521-8. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21520284

7. Popoff MR, Poulain B. Bacterial toxins and the nervous system: neurotoxins and multipotential toxins interacting with neuronal cells. Toxins (Basel) [Internet]. 2010 Apr [citado 25 May 2014];2(4):683-737. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22069606

8. Gu S, Jin R. Assembly and function of the botulinum neurotoxin progenitor complex. Curr Top Microbiol Immunol [Internet]. 2013 [citado 25 May 2014]; 364:21-44. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23239347

9. Dressler D. Five-year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins. Eur J Neurol [Internet]. 2012 Mar [citado 25 May 2014];19(3):385-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22035051

10. Habek M, Karni A, Balash Y, Gurevich T. The place of the botulinum toxin in the management of multiple sclerosis. Clin Neurol Neurosurg [Internet]. 2010 [citado 25 May 2014];112(7):592-6. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20615606

11. Gill HS, Kraft SP. Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm. Can J Neurol Sci [Internet]. 2010 [citado 25 May 2014];37(5):631-6. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21059510

12. Wabbels B, Jost WH, Roggenkämper P. Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm. J Neural Transm (Vienna) [Internet]. 2011 [citado 25 May 2014];19(3):118(6):925-43. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21221669

13. Bakheit AM, Zakine B, Maisonobe P, Aymard C, Fhedoroff K, Hefter H, et al. The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey. Int J Rehabil Res [Internet]. 2010[citado 25 May 2014];33(3):199-204. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20154631

14. Turner-Stokes L, Fheodoroff K, Jacinto J, Maisonobe P. Results from the Upper Limb International Spasticity Study-II (ULIS-II):a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. BMJ Open [Internet]. 2013 [citado 25 May 2014];3(6):e002771. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686177/

15. Grein S, Mander GJ, Fink K. Stability of botulinum neurotoxin type A, devoid of complexing proteins. Botulinum J [Internet]. 2011 [citado 25 May 2014];2(1):49-58. Disponible en: www.inderscienceonline.com/doi/pdf/10.1504/TBJ.2011.041815

16. Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H. Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins-a single cohort 4-year follow-up study. BMJ Open [Internet]. 2012 [citado 25 May 2014];2(4).pii: e000646. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22864418

17. Butler DP, Leckenby JI, Miranda BH, Grobbelaar AO. Botulinum Toxin therapy versus anterior belly of digastric transfer in the management of marginal mandibular branch of the facial nerve palsy: a patient satisfaction survey. Arch Plast Surg [Internet]. 2015 [citado 25 May 2014]; 42(6):735-740. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659987/

18. Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Experiment Ophthalmol [Internet]. 2014 [citado 20 Abr 2015];42(3):254-61. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23844601

19. Jankovic J, Tolosa E. Parkinson's Disease & Movement Disorders. 5th ed. Houston, Texas: Lippincott Williams & Wilkins; 2007.

20. Cillino S, Raimondi G, Guépratte N, Damiani S, Cillino M, Di Pace F, et al. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye (Lond) [Internet]. 2010 [citado 20 Abr 2014];24(4):600-7. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19648904

Downloads

How to Cite

1.
Martínez Brito BJ, Quintero Pérez M, Reyes Rosa M. Results of treatment of focal dystonia in adults with the use of botulinum toxin A3. Acta Méd Centro [Internet]. 2015 Dec. 23 [cited 2025 Jun. 28];9(4):21-30. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/291

Issue

Vol. 9 No. 4 (2015): October-December

Section

Original Articles

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).